home > news > detailed info

Business Continuity Plan - Message from Protagen Protein Services (PPS)

Protagen Protein Services

Following the recent COVID-19 outbreak, we at Protagen Protein Services (PPS) are preparing for all eventualities. Please be assured that PPS will continue to operate as normal providing you with all of the professional support and service you have to come to expect from us.

Given the gravity of the situation, and to protect our staff, clients, and communities from the spread of the virus, we have taken various measures within a scope of a Business Continuity Plan:

• We have taken proactive actions, i.e. home office and travel reduction where possible, to isolate and protect our office and lab operation and have set what we see as best practices and policies.
• We have a robust and site-redundant lab operating systems in service for many years to assure continuity in our analytical services, data analysis, security and communications with our customers. Additionally, we installed multiple redundancy by a two group lab operation for each our two labs in Germany and independent US operations.
• Particularly due to our size, location and secure lab profile, we are able to closely control people coming in or out of our company, and we have proactively implemented processes in separating and protecting our analytic operations, while shifting to teleconference and virtual meetings with any of our customers and partners.

Our staff is readily available via all of the normal channels when needed. Our Analytical Team will continue to offer first-class service and support. In case of urgent resources needed, please contact us.

We are determined to defy the pandemic and do the best we can in these times. Stay safe and stay in touch.

Martin Blüggel

phone +49 231 9742 61 00
email Protagen Protein Services (GmbH), Inselwiesenstraße 10, D-74076 Heilbronn
Print this page
Send to a friend
News and Press Releases

IONTAS Collaboration with F-star Enters Oncology Phase I Clinical Trial

Cambridge, UK,– 29 June 2021: IONTAS Limited (IONTAS), a leader in the discovery and optimization of fully human antibodies, today announces that F-star Therapeutics, Inc. (NASDAQ: FSTX), has dosed the first patients in a Phase 1 clinical trial, with FS222, a CD137/PD-L1 bispecific antibody.
More info >>

White Papers

Comparator Sourcing in Oncology Trials

Clinical Services International

This is an exciting time for oncology trials, year on year record numbers of therapeutics are launched and the indications for many drugs on the market are increasing rapidly. Immunotherapies and next generation biotherapeutics are being approved for more tumour types and a growing percentage of the late stage oncology pipeline are targeted biologics.
More info >>

Industry Events

Pharma Integrates 2021

16 November 2021, VIRTUAL CONFERENCE

Now in its tenth year, Pharma Integrates is a unique event bringing together pharma and healthcare leaders across the Pharmaceutical pipeline to address their needs, to share insights and create debate on crucial topics that influence the future of patient outcomes.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement